Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion type Assertion NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_head.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion description "[Between May 1986 and May 1987, 35 primary noninflammatory breast carcinomas (T3N0-N1M0) were studied by means of DNA flow cytometry (FCM-DNA) before and after each of three courses of preoperative chemotherapy (doxorubicin, vincristine, cyclophosphamide, methotrexate, and 5-fluorouracil) to assess initial nuclear DNA content, initial S-phase fraction (SPF), and the impact of chemotherapy on these parameters.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_provenance.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion evidence source_evidence_literature NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_provenance.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion SIO_000772 1728376 NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_provenance.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion wasDerivedFrom befree-2016 NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_provenance.
- NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_assertion wasGeneratedBy ECO_0000203 NP592564.RAC6d9DtpQ5Pmz2gr8Ce_MFkFmzZKFVbjmIWsRUQpevLU130_provenance.